Comparison of therapeutic effects between Limaprost alfadex and Gabapentin in cervical myelopathy patient: Randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230603001

Enrollment

Registered

2023-06-03

Start date

2022-01-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical spondylosis myelopathy CSM Gabapentin Limaprost alfadex

Interventions

Limaprost alfadex (5 mcg) 1 tab PO TID Naproxen (250 mg) 1 tab PO BID Omeprazole(20 mg) 1 tab PO OD AC Vitamin B6 (50) 1 tab PO OD,Gabapentin (300 mg ) 1 tab PO BID Naproxen (250 mg) 1 t

Experimental Drug,Active Comparator Drug

Intervention group,control group

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 20-80 years old 2. Patients who meet the diagnostic criteria in the following topics a. Symptom : Neck pain or aching pain down the arm or have numbness Weakness in arms, hands, abnormal gait b. physical examination : Intrinsic muscle weakness , Finger escape sign + , Grip and release + , lhermitte test + c. An MRI or CT scan showed narrowing of the spinal canal in the neck. together with spinal cord compression d. The diagnosis was confirmed by an Orthopedic spine surgeon. The diagnosis relies on a, b and d together, with or without c. 3. Cooperate consent to participate in the research project

Exclusion criteria

Exclusion criteria: 1. History of allergy to gabapentin or Pregabalin 2. History of allergies to NSAIDs, Opioids 3. Peripheral nerve entrapment and other pathology such as Tandem stenosis. 4. Take anti-platelet drugs (ASA), anticoagulant drugs 5. Received NSAID and Gabapentin treatment within 1 week prior to study participation. 6. History of end-stage chronic kidney disease 7. History of heart failure, ischemic heart disease 8. History of cirrhosis 9. History of peptic ulcer disease 10. History of all types of cancer 11. Persons diagnosed with cervical spondylosis with severe symptoms requiring surgery

Design outcomes

Primary

Measure	Time frame
Pain score 0 4 8 weeks after treatment Visual analog scale	—

Secondary

Measure	Time frame
Quality of life before - after treatment SF-36,Motor power , Sensory , Provocation test Before - After treatment Physical examination,Adverse effect In researching time Patient feed back	—

Countries

Thailand

Contacts

Public ContactKritamate Kongprom

Rajavithi hospital

kritamate13@gmail.com0919862913

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026